{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:59:24Z","timestamp":1777453164503,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Etravirine (ETR) is approved as a component of second or third-line antiretroviral treatment (ART) for children living with HIV. We assessed the outcomes of ETR-based ART in children in routine care in Europe and Thailand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data on children aged &lt;18\u00a0years at ETR start were pooled from 17 observational cohorts. Characteristics at ETR start, immunological and virological outcomes at 12 months, discontinuations, adverse events (AEs) and serious adverse events (SAEs) were described. Follow-up was censored at ETR discontinuation, death or last visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      177 children ever received ETR. At ETR start, median [IQR] age was 15 [12,16]\u00a0years, CD4 count 480 [287, 713] cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      , 70% had exposure to \u22653 ART classes and 20% had viral load (VL) &lt;50 copies\/mL. 95% received ETR in combination with \u22651 potent drug class, mostly protease inhibitor-based regimens. Median time on ETR was 24 [7, 48]\u00a0months. Amongst those on ETR at 12 months ( n=141), 69% had VL&lt;50 copies\/mL. Median CD4 increase since ETR start ( n=83) was 147 [16, 267] cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      . Overall, 81 (46%) discontinued ETR by last follow-up. Median time to discontinuation was 23 [8, 47] months. Common reasons for discontinuation were treatment simplification (19%), treatment failure (16%) and toxicity (12%). Eight children (5%) had AEs causally associated with ETR, all dermatological\/hypersensitivity reactions. Two were SAEs, both Stevens\u2013Johnson Syndrome in children on regimens containing ETR and darunavir and were causally related to either drugs; both resolved following ART discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Children receiving ETR were predominantly highly treatment-experienced, over two-thirds were virally suppressed at 12 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/13596535221092182","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T02:11:05Z","timestamp":1661566265000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand"],"prefix":"10.1177","volume":"27","author":[{"family":"European Pregnancy and Paediatric Infections Cohort Collabor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Lyons","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Thompson","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Chappell","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luminita","family":"Ene","sequence":"additional","affiliation":[{"name":"Clinical Department of Infectious Diseases (HIV Department), Dr. Victor Babe\u0219 Hospital for Infectious and Tropical Diseases, Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Galli","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Meyer Children\u2019s Hospital, Department of Health Sciences, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tessa","family":"Goetghebuer","sequence":"additional","affiliation":[{"name":"Hopital St Pierre, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzague","family":"Jourdain","sequence":"additional","affiliation":[{"name":"Institut de recherche pour le d\u00e9veloppement (IRD)-PHPT, Marseille, France"},{"name":"Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Noguera-Julian","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Department of Pediatrics, Sant Joan de D\u00e9u Hospital Research Foundation, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian R","family":"Kahlert","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Hospital Epidemiology, Children\u2019s Hospital of Eastern Switzerland and Cantonal Hospital, St Gallen, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[{"name":"Department for Children and Adolescents, Division for Stem Cell Transplantation and Immunology, University Hospital Frankfurt\/Main, Frankfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pope","family":"Kosalaraksa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pagakrong","family":"Lumbiganon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Khon Kaen University, Khon Kaen, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"Hospital of Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Marques","sequence":"additional","affiliation":[{"name":"Centro Hospitalar e Universit\u00e1rio do Porto, Porto, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa","family":"Navarro","sequence":"additional","affiliation":[{"name":"Hospital General Universitario \u201cGregorio Mara\u00f1\u00f3n\", Madrid, Spain"},{"name":"Universidad Complutense, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IISGM), Madrid, Spain"},{"name":"Red de Investigaci\u00f3n Translacional en Infectolog\u00eda Pedi\u00e1trica, RITIP, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Naver","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liubov","family":"Okhonskaia","sequence":"additional","affiliation":[{"name":"Federal Budgetary Institution \u201cRepublican Clinical Infectious Hospital\u201d of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipa","family":"Prata","sequence":"additional","affiliation":[{"name":"Hospital de Santa Maria\/CHULN, Lisbon, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and HIVNAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose T","family":"Ramos","sequence":"additional","affiliation":[{"name":"Departamento de Salud P\u00fablica y Materno-infantil, Universidad Complutense, Hospital Cl\u00ednico San Carlos, Instituto de Investigaci\u00f3n Sanitaria del Hospital Cl\u00ednico San Carlos (IdISSC), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Samarina","sequence":"additional","affiliation":[{"name":"The City HIV Centre, St Petersburg City AIDS Center, St Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Thorne","sequence":"additional","affiliation":[{"name":"University College London Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny","family":"Voronin","sequence":"additional","affiliation":[{"name":"Federal Budgetary Institution \u201cRepublican Clinical Infectious Hospital\u201d of the Ministry of Health of the Russian Federation, Saint-Petersburg, Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Turkova","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"},{"name":"Great Ormond Street Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giaquinto","sequence":"additional","affiliation":[{"name":"Paediatric European Network for the Treatment of AIDS (Penta), Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Judd","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-6037","authenticated-orcid":false,"given":"Intira J","family":"Collins","sequence":"additional","affiliation":[{"name":"MRC Clinical Trials Unit at UCL, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"bibr1-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix854"},{"key":"bibr2-13596535221092182","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.20.1.21930"},{"key":"bibr3-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12411"},{"key":"bibr4-13596535221092182","unstructured":"Janssen-Cilag-Ltd. Intelence: Summary of Product Characteristics (SmPC), (2020, accessed 10 January 2021)."},{"key":"bibr5-13596535221092182","unstructured":"Food and Drug Administration. Etravirine Cross Discipline Team Leader Review: Clinical Addendum. (2018, accessed 10 January 2021)."},{"key":"bibr6-13596535221092182","doi-asserted-by":"publisher","DOI":"10.2478\/abm-2010-0065"},{"key":"bibr7-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12217"},{"key":"bibr8-13596535221092182","unstructured":"Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/pediatric-arv. (2021, accessed 20 January 2022)."},{"key":"bibr9-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12141"},{"key":"bibr10-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2010.00907.x"},{"key":"bibr11-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000001638"},{"key":"bibr12-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000001843"},{"key":"bibr13-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328331a456"},{"key":"bibr14-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000002902"},{"key":"bibr15-13596535221092182","unstructured":"U.S Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, (Corrected version 2.1 - July 2017). https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables (2017, accessed 15 Dec 2017)."},{"key":"bibr16-13596535221092182","unstructured":"World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens, https:\/\/www.who.int\/hiv\/pub\/arv\/arv-update-2019-policy\/en\/(2019)."},{"key":"bibr17-13596535221092182","unstructured":"Penta HIV Guidelines Writing Group. Penta guidelines for first and second line antiretroviral treatment, https:\/\/penta-id.org\/hiv\/treatment-guidelines\/(2019, accessed 14 March 2020)."},{"key":"bibr18-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03508.x"},{"key":"bibr19-13596535221092182","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn292"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535221092182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535221092182","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535221092182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:06Z","timestamp":1777380786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535221092182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1177\/13596535221092182"],"URL":"https:\/\/doi.org\/10.1177\/13596535221092182","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"article-number":"13596535221092182"}}